Table 2 Baseline characteristics of chemotherapy-naïve mCRPC patients in the STRIVE and TERRAIN trials
Baseline characteristics | STRIVE | TERRAIN | ||
|---|---|---|---|---|
Enzalutamide (n = 128) | Bicalutamide (n = 129) | Enzalutamide (n = 184) | Bicalutamide (n = 191) | |
Age, years | ||||
 Median | 71 | 72 | 71 | 71 |
 Range | 46–87 | 50–90 | 50–96 | 48–91 |
Race, n (%) | ||||
 Black or African-American | 14 (10.9) | 15 (11.6) | 8 (4.3) | 10 (5.2) |
 White | 107 (83.6) | 111 (86.0) | 172 (93.4) | 176 (92.1) |
 Other | 7 (5.5) | 3 (2.3) | 4 (2.2) | 5 (2.6) |
Baseline weight, kg | ||||
 Median | 91.6 | 88.3 | 88.2 | 86.8 |
 Range | 58.5–166.6 | 52.7–181.8 | 57.0–184.1 | 56.0–143.5 |
Body mass index, kg/m2 | ||||
 Median | 30 | 29 | 28 | 28 |
 Range | 20–49 | 16–62 | 18–51 | 18–44 |
ECOG performance status, n (%) | ||||
 0 | 92 (71.9) | 92 (71.3) | 130 (70.7) | 146 (76.4) |
 1 | 36 (28.1) | 37 (28.7) | 54 (29.3) | 45 (23.6) |
Serum PSA, μg/L | ||||
 Median | 15.1 | 18.3 | 21 | 22 |
 Range | 0.0–1499.7 | 0.2–2849.7 | 0.6–5000 | 0.1–4681 |